IR-MED's PressureSafe device shows 94% sensitivity in detecting pressure injuries

Published 23/06/2025, 13:50
IR-MED's PressureSafe device shows 94% sensitivity in detecting pressure injuries

ROSH PINA, ISRAEL - IR-MED Inc. (OTCQB: IRME), a small-cap medical device company currently valued at approximately $6 million, announced interim results from its U.S. clinical study of PressureSafe, a handheld infrared spectroscopy device designed to assess pressure injuries before visible skin breakdown. According to InvestingPro data, analysts expect both sales and net income growth for the company this year.

The preliminary findings, based on 786 scans across 163 anatomical sites at Methodist Healthcare in San Antonio, Texas, showed the device achieved 94% sensitivity in assessing tissue at high risk for Stage 1 pressure injuries and suspected deep tissue injuries before skin breakdown. The study included a significant proportion of participants (61%) with darker skin tones. While the company's stock has seen a significant decline of over 80% year-to-date, analysts maintain a bullish outlook with a $3 price target, according to InvestingPro analysis.

Dr. Mary Lee Potter, Principal Investigator and Wound Care Specialist at HCA Healthcare, said the device offers "a rapid, objective tool to assess tissue risk, especially in patients with dark skin tones."

The interim results were presented at the HCA Healthcare & Galen College of Nursing Research Day in June. Dr. Potter will also present the findings at the 2025 ANCC Magnet/ANE Research Symposium in Atlanta on October 7.

PressureSafe is currently undergoing usability studies at multiple medical centers and is not yet commercially available. The technology aims to address pressure injuries, which account for $26.8 billion in U.S. healthcare spending and result in 60,000 deaths annually, according to the company's press release statement. For investors interested in deeper analysis of IR-MED's potential in this substantial market, InvestingPro offers additional insights through its comprehensive financial health metrics and 5 more exclusive ProTips.

The device is designed to provide assessment capabilities regardless of patient skin tone, potentially addressing disparities in pressure injury detection.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.